NASDAQ:MDWDMediwound Stock Price, Forecast & News

Mediwound's stock was trading at $2.31 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MDWD shares have decreased by 12.6% and is now trading at $2.02. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mediwound in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Mediwound.

Mediwound is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Mediwound.

Mediwound Ltd (NASDAQ:MDWD) issued its quarterly earnings data on Wednesday, May, 20th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the Zacks' consensus estimate of ($0.14) by $0.05. The biopharmaceutical company earned $4.44 million during the quarter, compared to the consensus estimate of $4.25 million. Mediwound had a net margin of 18.46% and a negative return on equity of 75.91%. View Mediwound's earnings history.

2 equities research analysts have issued 1 year price objectives for Mediwound's stock. Their forecasts range from $5.50 to $7.00. On average, they anticipate Mediwound's stock price to reach $6.25 in the next year. This suggests a possible upside of 209.4% from the stock's current price. View analysts' price targets for Mediwound.

News stories about MDWD stock have been trending somewhat positive recently, according to InfoTrie. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Mediwound earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutMediwound.

Mediwound saw a decrease in short interest in May. As of May 15th, there was short interest totaling 104,100 shares, a decrease of 13.4% from the April 30th total of 120,200 shares. Based on an average daily volume of 55,400 shares, the days-to-cover ratio is currently 1.9 days. Approximately 0.7% of the shares of the stock are short sold. View Mediwound's Current Options Chain.

Some companies that are related to Mediwound include Sundial Growers (SNDL), Happiness Biotech Group (HAPP), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN), True Drinks (TRUU), FitLife Brands (FTLF), GLG Life Tech (GLGLF), Tauriga Sciences (TAUG), Nutra Pharma (NPHC), Entia Biosciences (ERGO), Beleave (BE), Beleave (BE) and Rock Creek Pharmaceuticals (RCPIQ). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mediwound investors own include Opko Health (OPK), Blackstone Group (BX), Mastercard (MA), Wells Fargo & Co (WFC), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sorrento Therapeutics (SRNE), Alibaba Group (BABA) and Chubb (CB).

Mediwound trades on the NASDAQ under the ticker symbol "MDWD."

Mediwound's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (8.88%), Wells Fargo & Company MN (0.81%), BOKF NA (0.76%), Acadian Asset Management LLC (0.48%), Sargent Investment Group LLC (0.43%) and Harel Insurance Investments & Financial Services Ltd. (0.37%).

MDWD stock was sold by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd., Wellington Management Group LLP, BOKF NA, and Morgan Stanley.

MDWD stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Fortis Advisors LLC, Sargent Investment Group LLC, and Wells Fargo & Company MN.

Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MDWD stock can currently be purchased for approximately $2.02.

Mediwound has a market capitalization of $54.95 million and generates $31.79 million in revenue each year. The biopharmaceutical company earns $4.95 million in net income (profit) each year or $0.08 on an earnings per share basis. Mediwound employs 73 workers across the globe.

The official website for Mediwound is www.mediwound.com.

Mediwound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972-8932-4010 or via email at [email protected]